Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems

Research output: Contribution to journalReviewResearchpeer-review

Documents

  • Fulltext

    Final published version, 859 KB, PDF document

  • Manuel Eichenlaub
  • Stefan Pleus
  • Martina Rothenbühler
  • Timothy S. Bailey
  • Lia Bally
  • Ronald Brazg
  • Daniela Bruttomesso
  • Peter Diem
  • Elisabet Eriksson Boija
  • Marion Fokkert
  • Cornelia Haug
  • Rolf Hinzmann
  • Johan Jendle
  • David C. Klonoff
  • Julia K. Mader
  • Konstantinos Makris
  • Othmar Moser
  • James H. Nichols
  • John Pemberton
  • Elizabeth Selvin
  • Loukia Spanou
  • Andreas Thomas
  • Nam K Tran
  • Lilian Witthauer
  • Robbert J Slingerland
  • Guido Freckmann

Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.

Original languageEnglish
JournalDiabetes Technology & Therapeutics
Volume26
Issue number4
Pages (from-to)263-275
ISSN1520-9156
DOIs
Publication statusPublished - 2024

ID: 383887115